(Q45580188)

14 December 2017

title

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation (English)

1 reference

14 December 2017

1 reference

1 reference

6

Ronald N Jones

1 reference

14 December 2017

author name string

Martina Kinzig-Schippers

2

1 reference

14 December 2017

Lei Ma

4

1 reference

14 December 2017

Fritz Sörgel

5

1 reference

14 December 2017

Lois S. Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20851549

16 July 2024

Anne N. Nafziger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20851549

16 July 2024

George L. Drusano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20851549

16 July 2024

Joseph S. Bertino

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20851549

16 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20851549

16 July 2024

publication date

18 September 2010

1 reference

full work available at URL

14 December 2017

https://api.elsevier.com/content/article/PII:S0732889310002269?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

https://api.elsevier.com/content/article/PII:S0732889310002269?httpAccept=text/plain

16 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Diagnostic Microbiology and Infectious Disease

16 July 2024

published in

1 reference

14 December 2017

volume

68

1 reference

14 December 2017

issue

3

1 reference

14 December 2017

page(s)

251-258

1 reference

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

14 December 2017

cites work

7

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

16 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Prevention of resistance: a goal for dose selection for antimicrobial agents

16 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

16 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

16 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability

16 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Determining the value of antimicrobial surveillance programs

16 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

16 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

16 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

16 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

16 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

16 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps

16 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa

16 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

The pharmacodynamics of beta-lactams

16 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration?

16 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.06.012

16 July 2024

Identifiers

1 reference

14 December 2017

1 reference